Valeant Pharma (VRX) Tops Q4 EPS by 5c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Pharmaceuticals (VRX) PT Lowered to $18 at Jefferies
March 1, 2017 7:46 AM ESTJefferies lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $18.00 (from $22.00) while maintaining a Buy rating following Q4 result and outlook.
Analyst David Steinberg commented, "Q4 EPS of $1.26 was ~5% ahead of cons with revs just topping guidance ($2.28-2.38B) at $2.40B. More importantly,... More
